Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells by Voloshanenko, Oksana et al.
ARTICLE
Received 2 May 2013 | Accepted 13 Sep 2013 | Published 28 Oct 2013
Wnt secretion is required to maintain high levels
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Aberrant regulation of the Wnt/b-catenin pathway has an important role during the onset
and progression of colorectal cancer, with over 90% of cases of sporadic colon cancer
featuring mutations in APC or b-catenin. However, it has remained a point of controversy
whether these mutations are sufﬁcient to activate the pathway or require additional upstream
signals. Here we show that colorectal tumours express elevated levels of Wnt3 and Evi/Wls/
GPR177. We found that in colon cancer cells, even in the presence of mutations in APC or
b-catenin, downstream signalling remains responsive to Wnt ligands and receptor proximal
signalling. Furthermore, we demonstrate that truncated APC proteins bind b-catenin and key
components of the destruction complex. These results indicate that cells with mutations in
APC or b-catenin depend on Wnt ligands and their secretion for a sufﬁcient level of b-catenin
signalling, which potentially opens new avenues for therapeutic interventions by targeting
Wnt secretion via Evi/Wls.
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W
nt signalling pathways are highly conserved across
metazoans and have important roles in many
biological processes, including embryonic develop-
ment, tissue homeostasis and carcinogenesis1. Canonical Wnt
signalling through b-catenin is of particular importance for the
development of colorectal cancer, with more than 80% of
tumours carrying loss-of-function mutations in adenomatous
polyposis coli (APC) and about 5% carrying activating mutations
in b-catenin2,3. In the normal intestinal epithelium, Wnt
signalling regulates the proliferation and differentiation of
intestinal stem and progenitor cells. Mutations in APC and b-
catenin are among the earliest events of colon cancer
development and lead to hyperplasia in the intestinal crypts4,5.
Recent studies have shown that Wnt signalling activity is also
required in colon cancer cells during tumour progression and
metastasis6.
The secretion of Wnt proteins requires Evenness interrupted/
Wntless/G protein-coupled receptor 177 (Evi/Wls/GPR177)7–11.
This multipass transmembrane protein acts as a cargo receptor
for Wnt proteins, shuttling them from the Golgi to the plasma
membrane where they act in an autocrine or paracrine manner to
activate Wnt signalling pathways. Upon binding to receptors of
the Frizzled family and their coreceptors, Wnt proteins activate
different downstream signalling pathways. In the so-called
canonical pathway, signals are transmitted through Dishevelled
(Dvl) adaptor proteins, leading to the stabilization of cytosolic
b-catenin and its translocation to the nucleus. In the absence of
Wnt signalling, b-catenin degradation is initiated by the
‘destruction complex’, which comprises, among other proteins,
APC, GSK3b and Axin1. APC acts as a scaffold, binding
b-catenin and recruiting CK1a and GSK3b to phosphorylate
b-catenin. This event marks b-catenin for ubiquitination by the
SKP1–Cullin-1–F-box (SCFbKP1-) E3 ubiquitin ligase complex
and subsequently triggers its proteasomal degradation12. When
b-catenin translocates to the nucleus as a consequence of Wnt
signalling, it acts as a cofactor for transcription factors of the
T-cell factor (TCF) family, leading to the transcription of Wnt/
b-catenin target genes such as AXIN2, SMAD7, CCND1/CyclinD
and MYC.
Given that mutations in APC and b-catenin are thought to lead
to a constitutively active Wnt pathway that renders cells
insensitive to upstream regulation, many drug development
efforts for colon cancer have focused on downstream targets2,13.
However, other experimental data challenge the assumption that
mutant APC alone is sufﬁcient to sustain Wnt pathway activity.
For example, secreted Wnt antagonists such as the secreted
Frizzled-related proteins (SFRPs) have been found to attenuate
Wnt/b-catenin signalling in colorectal cancer cell lines carrying
APC mutations14,15; this observation has also been explained by
proposing novel, Wnt/b-catenin-independent functions for these
factors16,17. Other studies have shown that b-catenin expression
patterns across a colon tumour are heterogeneous, suggesting that
the Wnt pathway activity across a tumour can be variable
irrespective of the homogeneous distribution of the activated
b-catenin mutant protein throughout that tumour18–21. These
observations highlight the need to dissect the mechanisms that
underlie the effects of APC and b-catenin mutations on the Wnt/
b-catenin signalling cascade.
Here we show that the levels of both Wnt3 and Evi/Wls are
frequently higher in adenomas and differentiated carcinomas
than in normal colon epithelium. We also demonstrate that
interfering with the secretion of Wnt proteins in colon cancer cell
lines that harbour APC or b-catenin mutations impairs the ability
of the cells to proliferate and to form colonies in vitro and
tumours in vivo. We provide evidence that autocrine Wnt
secretion via Evi/Wls is required for maintaining the Wnt activity
in cell lines and tumour-initiating cells (TICs). Taken together,
these results support a model, wherein colon cancer cells acquire
the ability to secrete canonical Wnt proteins continuously, and
require such autocrine secretion for survival.
Results
Evi/Wls and Wnt3 are highly expressed in colon carcinomas. In
the normal mouse small intestinal epithelium, Wnt3 is highly
expressed in Paneth cells where it has a crucial role in maintaining
LGR5þ intestinal stem cells at the bottom of the crypt22,23. Here
we asked whether a similar expression pattern of Wnt3 and its
cargo receptor Evi/Wls can be detected in human colon tissue. To
this end, we stained normal human colon and matched carcinoma
tissue sections (from the same patient) for Wnt3 and Evi/Wls
protein, using Keratin20 and Eph receptor B2 as markers of cell
differentiation (Fig. 1a,b and Supplementary Fig. S1b)24. We found
that Wnt3 and Evi/Wls proteins were low or were not detectable in
enterocytes and goblet cells, whereas their expression was more
prominent in the underlying lamina muscularis mucosae (Fig. 1a).
In addition, high Wnt3 expression was observed in scattered cells,
which showed characteristics of endocrine and Paneth-like25 cells
localized at the bottom of the crypt, with eosinophilic granula in
the cytoplasm and the basal nuclei. These results suggest that an
important source of Wnt proteins in the human colon is located at
the bottom end of the crypts.
Surprisingly, in carcinoma sections from the same patients,
Evi/Wls and Wnt3 staining was stronger and detectable
throughout the epithelium (Fig. 1b). To conﬁrm these data, we
also stained tumour tissue arrays for Evi/Wls and Wnt3 (Fig. 1c;
representative immunohistochemical stainings are shown in
Supplementary Fig. S1b). Wnt3 and Evi/Wls expression in the
epithelial cells of normal colon tissue (colon) was generally
weaker compared with tumuor tissues. However, it was elevated
in adenomas and showed strong expression in well- (G1) and
moderately (G2) differentiated (adeno-) carcinomas, whereas
poorly (G3) differentiated tumours showed heterogeneous Evi/
Wls expression (Fig. 1c). Our expression data are also consistent
with the TCGA messenger RNA expression data set (Oncomine,
www.oncomine.org, TCGA)3, which shows that the Wnt3, Wnt1
and Wnt3a mRNAs (Fig. 1d and Supplementary Fig. S1c) are
more highly expressed in colorectal adenocarcinomas than in
normal colon/rectum.
Next, we tested whether overexpressing the cargo receptor Evi/
Wls in colon cancer cells leads to an increase in Wnt signalling
activity, as previously shown in embryonic stem (ES) cells10. As
illustrated in Supplementary Fig. S1d, the overexpression of Evi/
Wls in the colon cancer cell line HCT116 led to a twofold increase
in Wnt reporter activity, indicating that the increased secretion of
Wnt proteins can upregulate canonical signalling.
Taken together, our data provide evidence that Wnt secretion
could have a functional role in colorectal carcinomas, and that
colorectal carcinoma cells have acquired the ability to secrete Wnt
ligands in an autocrine manner.
Evi is required for high levels of Wnt pathway activation. To
investigate the requirements for Evi/Wls expression in colon
cancer cells that harbour mutations in APC or b-catenin, we
chose two colon cancer cell lines: DLD1 (APC mutation; trun-
cated protein) and HCT116 (b-catenin mutation, loss of phos-
phorylation site S45). Short hairpin RNA (shRNA)-mediated
silencing of the Evi/Wls signiﬁcantly reduced lymphoid enhancer
factor (LEF)/Wnt-reporter26 induction to levels comparable to
those achieved by Bcl9 knockdown, an essential transcriptional
cofactor for the expression of Wnt/b-catenin target genes (Fig. 2a
and Supplementary Fig. S2a). This effect was rescued by adding
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3610
2 NATURE COMMUNICATIONS | 4:2610 | DOI: 10.1038/ncomms3610 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
Percentage bin of stained cells
St
ai
ni
ng
 in
te
ns
ity
0
1
2
3
0
1
2
3
Colon
0 1 2 3 4
Adenoma
0 1 2 3 4
G1
0 1 2 3 4
G2
0 1 2 3 4
G3
0 1 2 3 4
Evi/W
ls
W
nt3
0 2 4 6 8 10
No. of tumours
EphB2CK20
Evi/Wls Wnt3
Wnt3
Lo
g 2
 
m
e
di
an
 c
en
tre
d 
ra
tio
0.0
1.0
–1.0
–2.0
2.0
–3.0
Co
lon
 (19
)
Re
ctu
m 
(3)
Ad
en
oc
arc
ino
ma
(10
1)
Wnt3
***P =7.59E–11, fold change = 2.9
Carcinomab
d
c
a
EphB2 CK20
Evi/Wls Wnt3
Normal colon
20 μm
***
Figure 1 | Evi/Wls is highly expressed in colon tumours. (a,b) Immunohistochemical staining of normal or carcinoma tissue sections from colon, using
the indicated antibodies. Images are representative of ﬁve cases. (a) In normal tissue, Evi/Wls expression is mostly undetectable, whereas Wnt3 is
weakly expressed in most epithelial cells but more highly expressed in the Paneth-like/endocrine cells, which have a granular appearance (arrow).
Keratin20 staining marks the top of the intestinal crypts and Eph receptor B2 staining the bottom. (b) In matched colon carcinomas, Evi/Wls and Wnt3 are
highly expressed. (a,b) Scale bars, 60mm, Wnt3 (enlarged) 20mm. (c) Evi/Wls and Wnt3 are overexpressed in colon cancer. Results of immunostainings
for Evi/Wls and Wnt3 on a colon cancer tissue array. Scores provided independently by three different investigators are shown as average. Staining
intensity: 0¼ no staining, 1¼weak staining, 2¼moderate staining, 3¼ strong staining; percentage bin of cells: 0¼o10%, 1¼ 10–25%, 2¼ 25–50%,
3¼ 50–75%, 4¼475%). Grey scale represents the number of tumours. (d) Wnt3 is overexpressed in adenocarcinomas. Microarray-based expression
data (Oncomine database, TCGA data set) were analysed for the expression of Wnt3 in normal colon(19)/rectum(3) versus adenocarcinomas (101).
Preprocessed data from the array is log2-transformed and median-centred. The box plots show medians as line within the box, 25th and 75th percentiles as
sides of the box, 10th and 90th percentiles as error bars, and outliers as circles. Signiﬁcance of the differences in expression was calculated using the
Student’s t-test. The speciﬁcity of the Wnt3 antibody was tested by knockdown experiments (Supplementary Fig. S1a). Evi/Wls antibody is described in
Augustin et al.10
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recombinant Wnt3a (Supplementary Fig. S2b). Furthermore,
knockdown of Evi/Wls with a doxycycline (dox)-inducible
shmirRNA led to downregulation of the canonical Wnt target
gene AXIN2 in both DLD1 and HCT116 cells (Fig. 2b), an effect
that was likewise rescued by applying recombinant Wnt3a
(Supplementary Fig. S2c,d).
RNA interference (RNAi)-mediated downregulation of Evi/
Wls reduced the phosphorylation of Lrp6 on Ser1490 in both
DLD1 and HCT116 cells, conﬁrming that pathway activity was
reduced at the receptor level (Fig. 2c)27,28. Evi/Wls depletion in
these cell lines also reduced the levels of active b-catenin (non-
phosphorylated-S33/S37/T41) and of Axin2 (Fig. 2c). To conﬁrm
the speciﬁcity of knockdown, we rescued Wnt pathway activation
in HEK293T cells after knockdown of Evi/Wls, using modiﬁed
Evi/Wls expression constructs29 not targeted by the short
interfering RNAs (siRNAs; Supplementary Fig. S3a). These
ﬁndings suggest that Evi/Wls activity contributes to the activation
of canonical Wnt signalling in the presence of an APC or
b-catenin mutation.
Next, we tested whether blocking Wnt secretion using IWP12,
an inhibitor of the porcupine protein, the Wnt acyl-transfer-
ase30,31, interferes with Wnt activity in HCT116 cells. The results
presented in Supplementary Fig. S3b were similar to those
obtained for Evi/Wls silencing, supporting a model wherein Wnt
secretion is required for the activity of the canonical Wnt
pathway.
Recently, it has been shown that R-spondins bind to Lgr5 to
activate Wnt signalling32–34. Thus, we tested whether the effect of
Evi/Wls silencing can be rescued by adding recombinant
R-spondin1. As shown in Supplementary Fig. S3c–e, R-spondin1
could not rescue Wnt signalling in colon cancer cells when Evi/
Wls was depleted, in contrast to control experiments.
In summary, these results indicate that even in the presence
of the APC or b-catenin mutations, canonical Wnt signalling
in colon cancer cells depends on Wnt secretion. Depletion of
Evi/Wls leads to an almost complete loss of canonical Wnt
pathway activity, which cannot be rescued by the addition of
R-spondin.
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Figure 2 | Evi/Wls is required to maintain canonical Wnt signalling in colon cancer cell lines. (a) Evi/Wls depletion reduces canonical Wnt
signalling. DLD1 and HCT116 TCF4/Wnt reporter-colon cancer cells were transduced with lentivirus introducing a control or Evi shRNA construct.
Luciferase assay was normalized to viability assessed in parallel using the CellTiterGlo assay. Results of three (for DLD1) and ﬁve (for HCT116) independent
experiments are shown as mean±s.e.m. (b) Silencing of Evi/Wls regulates the Wnt target gene expression. DLD1 and HCT116 cells were transduced with a
dox-inducible shmirEvi#1 construct and treated with or without dox. After 96 h, the cells were analysed for the expression of AXIN2 and EVI/WLS mRNAs
by quantitative PCR. Results of four independent experiments are shown as mean±s.e.m. (c) Silencing of Evi/Wls reduces the level of active b-catenin in
DLD1 and HCT116 cells, which express mutated APC or b-catenin, respectively. DLD1 cells were transfected with the indicated siRNAs for 120 h,
and HCT116 cells were transfected for 72 h. Subsequently, the cells were lysed and western blotting was performed with the indicated antibodies. b-Actin
served as the loading control. The reduction of total Lrp6 in b-catenin knockdown cells, which is consistently observed in DLD1 cells, may be a consequence
of reduced b-catenin levels at the adherent junctions59.
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Mutated APC and upstream regulation of Wnt signalling.
Next, we investigated whether the presence of Wnts is required
for canonical signalling in colon cancer cell lines with mutant
APC. RNAseq data from seven colon cancer cell lines indicated
that several canonical Wnt ligands are expressed in each cell line,
the most prominent among these being Wnt3 and Wnt10b
(Supplementary Fig. S4a). To test whether these ligands are
secreted and functional, we cocultured SW480 and DLD1 cells
with a MDA-MB231 or HEK293T reporter cell line. We found
that both colon cancer cell lines induced canonical Wnt signalling
in a cell-number-dependent manner (Fig. 3a and Supplementary
Fig. S4b,c), producing a range of reporter activity similar to that
observed when recombinant Wnt3a was applied (Supplementary
Fig. S4b). To exclude the possibility of confounding effects from
increased reporter cell proliferation, we assessed the activity of a
TCF/LEF–GFP reporter at the single-cell level by ﬂuorescence-
activated cell sorting. Consistent with our results from the luci-
ferase assays, coculturing the reporter cell line with SW480 cells
enhanced TCF/LEF–GFP ﬂuorescence in reporter cells in a dose-
dependent manner (Supplementary Fig. S5a). These experiments
indicated that colon cancer cells secrete functional Wnt proteins.
Next, we investigated whether the Evi/Wls phenotype is
equivalent to that resulting from the loss of canonical Wnts.
Depleting HCT116 cells of Wnt3 and Wnt3a, and DLD1 cells of
Wnt3 (Fig. 3b), strongly reduced the reporter activity. Silencing
of Wnt3a was rescued by adding recombinant Wnt3a
(Supplementary Fig. S5b). Combined knockdown of both Wnt3
and Wnt3a led to a further reduction of Wnt signalling
(Supplementary Fig. S5c). We also observed reduced expression
of the Wnt target genes AXIN2 and SMAD7 (Supplementary Fig.
S5d), a reduction of Lrp6 phosphorylation (Ser1490) and a
decrease in Axin2 protein levels (Fig. 3c) after RNAi-mediated
silencing of Wnt3 or Wnt3a. As expected, the ability of the Wnt
ligands to activate signalling was dependent on the presence of
Evi/Wls in the secreting cells (Fig. 3d). Consistent with these
ﬁndings, silencing of Lrp6, Dvl1 and Dvl3 led to a decrease in
TCF4/Wnt-reporter activity, despite the presence of APC and b-
catenin mutations (Fig. 4a), and silencing of Dvl1 and Dvl3 led to
downregulation of AXIN2 mRNA (Fig. 4b).
In summary, colon cancer cell lines express canonical Wnt
ligands, whose Evi/Wls-dependent secretion is regulating cano-
nical Wnt signalling, regardless of the presence of mutated APC
or b-catenin.
Truncated APC can regulate canonical Wnt pathway. Eighty
per cent of colon cancers have biallelic APC mutations35, often
with complete lack of expression from one allele and expression
of a truncated from the other. Previous studies have indicated
that depletion of APC in colon cancer cells can activate canonical
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Figure 3 | Wnt secretion is required to maintain canonical Wnt signalling in colon cancer cell lines. (a) DLD1 and SW480 colon cancer cells activate the
Wnt pathway in cocultured MDA-MB231 reporter cells. DLD1 or SW480 cells were cocultured with MDA-MB231 reporter cells stably transduced
with a TCF/LEF reporter (1,500 cells) at the indicated ratio for 48 h. Next, cells were lysed and luciferase activity was measured. (b) Silencing of Wnt3
in DLD1 and HCT116 cells stably transfected with a TCF4/Wnt reporter reduces canonical Wnt signalling activity. Both cell lines were transfected
with the indicated siRNAs. HCT116 cells were incubated for 72 h and DLD1 cells for 96 h before read-out. Luciferase levels were normalized to cell
survival assessed by a CellTiterGlo assay performed in parallel. (c) Silencing of Wnt3a or Wnt3 reduces Axin2 protein expression. HCT116 cells were
transfected with the indicated siRNAs for 72 h. Cell lysates were used for western blotting with indicated antibodies. b-Actin served as the loading control.
(d) Evi/Wls knockdown in DLD1 cells reduces the induction of TCF/LEF reporter activity in coseeded MDA-MB231 reporter cells. Coculture of cells
was conducted as described in a. Half times more DLD shEvi cells than shCtrl cells were seeded to compensate for reduced viability. (a,b,d) Data
from three independent experiments are presented as mean±s.e.m.
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Wnt signalling36–39. To test whether truncated APC alleles
have residual ability to regulate downstream Wnt signalling
components and whether such activity can be reduced further, we
assessed the effect of RNAi-mediated APC silencing on TCF/LEF
and TCF4/Wnt reporter levels in DLD1, HT29 and HCT116 cells
(Supplementary Fig. S6a). In each of these cell lines, reducing
APC expression induced reporter expression. We observed a
particularly strong effect in HT29 cells, in which the truncated
APC protein is longer than that in DLD1 cells (Supplementary
Fig. S6a). In general, induction of AXIN2 mRNA appeared to
correlate with the length of the truncated APC proteins (Fig. 5a),
although we cannot completely exclude the possibility that
variability in RNAi efﬁciency affected the results obtained for
different cell lines (Supplementary Fig. S5b). APC silencing in
DLD1 cells with different distinct APC siRNAs led to repro-
ducible upregulation of AXIN2 (Supplementary Fig. S6c). These
results are consistent with previous studies showing that
truncated APC proteins remain capable of modulating the Wnt
pathway signalling.
Truncated APC retains functions in regulating Wnt signalling.
Our experiments indicated that colon cancer cell lines require
canonical Wnt ligands for full pathway activation and cell sur-
vival, regardless of the presence of mutations in APC or b-cate-
nin. We hypothesized that the mutant proteins might retain
partial function, shifting the balance between activators and
inhibitors of the Wnt/b-catenin pathway, rendering it more
sensitive to changes in signal ﬂow from upstream components.
Previous work using overexpression constructs of APC fragments
showed that it can retain b-catenin binding ability and reduce
signalling activity40–42. Su et al.43 also proposed that mutated
APC has impaired function in transferring phosphorylated
b-catenin for ubiquitylation. We therefore examined the
biochemical effects of clinically found mutant forms of
endogenous APC on destruction complex formation and Wnt/
b-catenin pathway activity.
As knockdown of truncated APC (1,360–1,560 aa) led to an
increased expression of the Wnt target gene AXIN2
(Fig. 5a)36,37,39, we hypothesized that this protein may retain its
ability to act as a scaffold for components of the destruction
complex. We tested this by immunoprecipitating the destruction
complex from Colo320, Caco2, DLD1 and RKO cells (truncations
of 811, 1,367 and 1,430 aa, and full-length APC, respectively).
As shown in Fig. 5b, endogenous APC, Axin1 and GSK3b
co-immunoprecipitated with b-catenin in all cases, indicating that
these truncated APC proteins retain the ability to bind b-catenin.
Next, we evaluated whether the truncated APC proteins
supported the formation of destruction complex and induced
phosphorylation of b-catenin. We co-immunoprecipitated endo-
genous APC, Axin1 and GSK3b from DLD1 and SW480 cells. We
detected b-catenin phosphorylation at sites S33 and S37 (as
also shown in refs 43,44), as well as the presence of the
major components of the destruction complex (Fig. 6a and
Supplementary Fig. S7a), indicating that truncated APC proteins
are partly functional. Thus, loss of b-catenin-binding sites in
colon cancer cells, such as DLD1 and SW480, leads to a reduction
in APC levels rather than its complete inactivation.
We also investigated whether a reduction in APC functionality,
although insufﬁcient to activate the pathway on its own, sensitizes
cells to the Wnt ligands. We used RKO that expresses wild-type
APC and shows only basal Wnt pathway activity as a model
system. To assess the effects of a partial reduction of APC levels,
we stably transduced RKO TCF4/Wnt-reporter cells with shRNA
constructs that target APC at different efﬁciencies of knockdown,
as assessed by their effects on expression of the AXIN2 mRNA
(Fig. 6b,c). We found that efﬁcient reduction of APC expression
(85% reduction, shAPC#2) induced strong reporter activity, even
in the absence of the Wnt3a ligand. In contrast, moderate
downregulation of APC expression (50% reduction, shAPC#1)
did not induce the reporter by itself, but resulted in a stronger
response when combined with exposure to Wnt3a ligand
(Fig. 6b). We further tested the effects of APC levels in HEK293T
cells that had been transfected with various siAPCs and treated
with Wnt3a. Although partial silencing of APC (using either
siAPC#1 or siAPC pool) did not induce TCF4/Wnt-reporter
activity on its own, we observed a stronger induction when
combined with Wnt3a treatment (Supplementary Fig. S7b,c).
Together, these ﬁndings indicate that colon cancer cells
expressing truncated APC can assemble a partially functional
destruction complex. We conclude that truncated APC does not
lead to full pathway activation, but can instead sensitize cells to
upstream signals.
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Figure 4 | Wnt pathway components at the receptor level are required
for canonical activation in colon cancer cells. (a) Knockdown of Lrp6, Dvl1
or Dvl3 reduces Wnt reporter activity in HCT116 and DLD1 cells. Cells
stably transfected with a TCF4/Wnt reporter were reverse transfected with
the indicated siRNAs and assessed for luciferase activity 72 h later.
(b) Silencing of Dvl1 and Dvl3 reduces Wnt target gene expression in DLD1
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Evi is required for the proliferation of colon cancer cells. To
evaluate whether Wnt secretion is required for the proliferation of
colon cancer cells, we stably transduced colon cancer cell lines
with lentiviral shRNA constructs targeting the Wnt cargo
receptor Evi/Wls. Knockdown of Evi/Wls reduced the viability of
HCT116 cells compared with cells treated with control shRNAs
and the cells accumulated in G2 phase, similar to cells deﬁcient
for b-catenin (Supplementary Figs S8 and S9a). Comparable
viability effects were observed in cells expressing truncated forms
of APC (Supplementary Fig. S9b,c). To study the effect of Evi/Wls
downregulation on long-term cell survival, we performed
clonogenicity assays in HCT116, DLD1 and SW480 cells. As
shown in Fig. 7a, Evi/Wls knockdown decreased colony forma-
tion relative to that measured in controls.
To assess the requirement of Evi/Wls in the survival of colon
cancer cells in vivo, we injected shRNA-transduced HCT116
or DLD1 cells (Fig. 7b,c) subcutaneously into NOD/SCID
(non-obese diabetic/severe-combined immunodeﬁciency) mice.
Expression of the Evi shRNA delayed or abrogated tumour
formation during the observation period (P¼ 0.000201, log-rank
test), an effect that was conﬁrmed with dox-inducible shmirRNA
constructs (shmirEvi#1 and #2; Fig. 7d and Supplementary Fig.
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S9d). These results demonstrate that silencing of the Wnt cargo
receptor Evi/Wls reduced both the initial engraftment of the
tumour and subsequent tumour growth.
Evi is important for the survival of colon cancer stem cells.
Vermeulen et al.21 showed that colon cancer stem cells are
characterized by high Wnt activity, which is essential for stemness
capacity of these cells. We hypothesized that Wnt signalling in
these cells might be dependent on canonical Wnts and Evi/Wls
expression in an autocrine or a paracrine manner, even in the
presence of APC mutation.
To investigate the role of Wnt secretion in TICs, we enriched
these cells from primary human colorectal cancer tissue or
derived metastases from three patients (P1–3) in serum-free
medium in the presence of cytokines. Under these conditions,
ﬂoating tumour spheroids are formed, which are enriched for
self-renewing TICs and depleted of non-neoplastic cells45. P1 and
P3 TICs harbour a truncated APC, whereas in P2 cells no
truncations of APC was detected (Fig. 8a). We conﬁrmed that the
three TICs expressed Evi/Wls and Wnt3 on an mRNA level.
We then tested whether truncated APC in colon cancer stem
cells is functional as shown above for colon cancer cell lines.
Consistently, we found that GSK3b and Axin1 bind to truncated
APC and b-catenin in all three spheroid cultures independent of
their APC mutation status (Fig. 8a). We further tested whether
inhibition of Wnt secretion by a Porcupine inhibitor (IWP12)
reduced the LEF/TCF–Wnt-reporter signalling in TICs with
truncated APC. Similar to colon cancer cell lines, inhibition of
Wnts secretion led to a reduction of Wnt signalling and reduces
viability of these cells (Fig. 8b,c).
Taken together, we conclude that high Wnt pathway activation
in primary colon cancer cells relies on Wnt secretion, despite
mutation in APC, indicating that the level of Wnt signalling is
modulated by the secretion of Wnt proteins.
Discussion
In colon cancer, mutations in APC or b-catenin are known to be
tightly associated with the transformation of normal epithelia,
leading to dysplasia and early adenomas. However, the functional
effects of these mutations on the Wnt/b-catenin signalling
pathway and the mechanisms whereby they contribute to
carcinogenesis are not yet fully understood. Here we provide
evidence that sustained Wnt secretion is important for the
proliferation and survival of colon cancer cells, both ex vivo and
in vivo. Cells carrying mutations in APC or b-catenin are still
dependent on the Wnt/b-catenin pathway activation upstream of
the b-catenin destruction complex (Fig. 9). Blocking upstream
signalling by depleting the Wnt cargo receptor Evi/Wls
signiﬁcantly reduces the proliferation of colon cancer cells.
Our results suggest that truncations of the APC tumour
suppressor do not render cells independent of exogenous Wnt
ligands, but rather lower the threshold of pathway activation by
Wnt proteins.
Our ﬁndings are interesting with regards to the observation
that extracellular inhibitors of the Wnt/b-catenin signalling, Dkk4
and Sfrps, are frequently downregulated in colorectal cancers14,15.
These proteins had been proposed to have novel functions given
the earlier assumption that mutations in APC or b-catenin would
render cells completely independent of canonical Wnt/b-catenin
signalling. Our results offer a different explanation: as Wnt/
b-catenin signalling remains critical for proliferation, reduced
expression of secreted Wnt/b-catenin antagonists and high
expression of Wnts and Evi/Wls promotes tumourigenesis.
The discovery of Evi/Wls as the cargo receptor for all Wnt
proteins opened new avenues for addressing whether the
production of Wnt ligands is required in cells that harbour
APC or b-catenin mutations. Evi/Wls was found to be essential
during development, because it is required for the export of all
Wnt proteins9,11. We observed increased expression of Evi/Wls
and Wnt ligands in colon cancers, and detected them throughout
the whole tissue, as opposed to weak or very localized expression
in healthy tissue (for example, Paneth-like cells, lamina
muscularis mucosae). This suggests that colon cancer cells are
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not only dependent on secreted Wnt ligands but also acquire
autocrine Wnt secretion capabilities. Notably, upregulation of
Wnts or Evi/Wls in colorectal cancer is associated with lower
overall survival. Consistently, TCGA recently showed that
colon cancer (tissues) display upregulation of Fzd10 and
downregulation of DKK1-4 mRNA levels3. This, as well as
the silencing of SFRPs, supports a model whereby the
destruction complex is regulated by upstream signals in
colorectal cancers.
These results also provide possible explanations for the uneven
distribution of nuclear b-catenin20,46 and the clustering of
mutations in APC47 in colon cancer. Mutations in APC most
often occur in the mutation cluster region (1,286–1,513 aa),
whereas a complete deletion of the APC locus is extremely
rare36,39,48,49. The retention of truncated APC has alternatively
been attributed to its role in cell division50,51, C-terminal binding
protein (CtBP)-dependent oligomerization52 or to limit excessive
levels of b-catenin in the nucleus53,54. It has also been proposed
that certain truncations of APC are selected to ensure that the
Wnt/b-catenin signalling pathway is activated to a degree optimal
to support tumour growth37,47. Regulation of b-catenin in colon
cancer cells could also be dependent on the APC-like protein, the
closest homologue of APC55. Our results are consistent with
previous studies on overexpressed APC protein fragments of
different length, which were shown to retain the b-catenin-
binding ability and reduce the signalling activity40–42.
Importantly, such a model requires that mutant forms of APC
remain, at least in part, a functional component of the destruction
complex. Accordingly, truncating mutations in APC represent
hypomorphic rather than complete loss-of-function alleles, as
suggested by Gaspar and Fodde38, based on experiments in
familial adenomatous polyposis (FAP) mouse models. Genetic
studies in mice also demonstrated that APC truncations select for
a certain amount of Wnt/b-catenin pathway activation and show
a dosage effect in TopFlash reporter assays conducted in mouse
ES cells47,56,57. Our study provides further mechanistic evidence
that endogenous truncated APC indeed retains the ability to bind
b-catenin. Notably, APC proteins have several b-catenin-binding
repeats (15 amino-acid repeats (AARs) and 20 AARs), which
enable the wild-type form to bind to multiple b-catenin proteins
(Figs 5a and 8). Truncated APC proteins that have been
associated with colorectal cancer usually retain several of these
AAR repeats. Thus, they have the ability to productively engage
b-catenin in the destruction complex. Further, we observed that
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even the shortest APC protein (in Colo320 cells) is able to bind to
b-catenin despite a complete lack of known b-catenin-binding
repeat regions, indicating that additional interfaces between APC
and b-catenin may exist. It has recently been shown that partial
silencing of APC can lead to colon cancer in the absence of
biallelic mutations in APC49. This directly relates to our ﬁnding
that partial reduction of APC can sensitize RKO cell to Wnt
ligands, arguing that mutations in APC create a special situation
of reduced b-catenin binding and processing ability. Taken
together, these data support a model, whereby colon cancer cells
with truncated APC remain susceptible to regulation by upstream
signals.
Do colon cancers create their own Wnt-dependent niche? High
Wnt pathway activity is essential to maintain the stem cell and
transient amplifying progenitor compartment in intestinal crypts,
and elevated Wnt/b-catenin pathway activity is associated with
stem cell signatures in cancer. It is tempting to speculate that
colon cancer cells generate a ‘niche’ that enables them to retain an
undifferentiated and stem cell-like behaviour, whereas non-
cancerous colon stems cells require the crypt microenvironment
to provide Wnt and other ‘stemness’ signals22. In the case of
tumours, the secretion of Wnt ligands and autocrine activation of
canonical receptors may have a crucial role in maintaining
stem cell populations independent of signals from the micro-
environment. Thus, despite the presence of pathway-activating
mutations in APC or b-catenin, the survival of colon cancer cells
remains dependent on secreted Wnt ligands, and thus requires
the activity of the Wnt cargo receptor Evi/Wls. The expression
levels of both Wnt3 and Evi/Wls correlate with the degree of
colon tumour differentiation, that is, the grade, which in turn
correlates with prognosis24.
The development of small-molecule Wnt antagonists for the
treatment of colon cancer has focused on targets downstream of,
or at the same level as, the destruction complex. Large-scale
sequencing of human colon cancers has revealed recurrent
genetic aberrations in a number of signal transducers, including
components of the canonical Wnt pathway58. In addition,
functional screening has uncovered a number of potential
targets that act just upstream of the destruction complex. Our
results indicate that the pathway can be inhibited further
upstream, for example, through inhibitors of Wnt production
acting at the level of Porcupine or the Wnt cargo receptor Evi/
Wls to regulating Wnt signalling in colon tumours at the site of
production.
Methods
Cell culture. All cell lines were obtained from ATCC. HEK293T, MDA-MB231
(DMEM; Gibco), HCT116, HT29 (McCoy’s; Gibco), LoVo, SW480 and DLD1
(RPMI; Gibco) cells were cultured without antibiotics, unless they were stably
transfected or transduced. All media were supplemented with 10% fetal bovine
serum (PAA). HCT116 TCF4/Wnt cells were cultured in the presence of
50 mgml 1 hygromycin B, and HCT116 TCF/LEF cells were cultured in the
presence of 10mgml 1 puromycin.
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Primary colon cancer-initiating cells. Primary human colorectal cancer or
derived metastasis were obtained from the University Hospital Heidelberg in
accordance with the Declaration of Helsinki. From each patient, informed consent
on tissue collection as approved by the University Ethics Review Board was
available. Primary human tissue was minced and digested using dispase (BD
Biosciences), ﬁltered and cells were seeded in ultralow attachment in cancer stem
cell (CSC) media under serum-free conditions with the addition of ﬁbroblast
growth factor (FGF) basic (10 ngml 1) and epidermal growth factor (EGF)
(20 ngml 1; both from R&D Systems) to allow spheroid formation45. For
experimental seeding, spheroid cultures derived from three individual patients (P1
(K-Ras, p53 mutant), P2 (p53 mutant) and P3 (K-Ras, PI3CA, p53 mutant)) were
dissociated to a single-cell solution by mechanical disruption via pipetting or by
accutase treatment. To generate stable LEF/TCF–Wnt-reporter spheroid cultures,
P3 spheroids were dissociated, lentivirally transduced using Viromag R/L beads
(OZbiosciences) and subsequently cultured in the presence of 5 mgml 1
puromycin to select for transduced cells.
Quantitative PCR. Complementary DNA was prepared from 0.5 or 2 mg total
RNA, using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo
Fischer Scientiﬁc). Subsequently, the cDNA was diluted to 5 ng ml 1 and used for
quantitative PCR on the Lightcycler 480 (Roche), using the universal probe library
system (Roche) in a 384-well format. GAPDH and UBC were used as reference
genes for relative quantiﬁcation. Oligos for quantitative PCR are shown in
Supplementary Table S1.
Cell-based assays and recombinant proteins. siRNAs were obtained from
Ambion (Applied Biosystems). Cells were transfected using a total of 0.1%
DharmaFECT 1 (Thermo Fischer Scientiﬁc) or RNAiMax (Invitrogen). For plas-
mid transfection, cells were transfected with 10–60 ng DNA (total) per 384-plate
well using TransIT reagent (VWR). Cell viability was determined using the Cell-
TiterGlo assay (Promega) according to the manufacturer’s protocol. Recombinant
mouse Wnt3a(315-20) was obtained from PeproTech and mouse recombinant
R-spondin1 (3474-RS) from R&D Systems. siRNA sequences are shown in
Supplementary Table S2. Full sized scans of all western blots are provided in
Supplementary Figure S10.
Generation of stable cell lines. To generate stable Evi, control, CTNNB1
knockdown pools or TCF/LEF or LEF–GFP Wnt-luciferase reporter cell lines, we
used lentiviral transduction with the indicated constructs. Viral particles were
produced using the lentiviral packaging vectors pMDM2-VSVG, psPAX2 and the
vector of interest transfected in the ration 3:1:2 into HEK293T cells. Supernatants
were collected and ﬁltered (45 mm) 36–42 h post transfection. Two hundred to
500 ml of the supernatant and 2.5 mgml 1 of polybryne were added to the six-well
plate/T125 ﬂask of cells, plate/ﬂask was centrifuged at 2,000 g for 1 h and then
incubated for 24–48 h in standard conditions. Stable cell lines were selected in the
presence of 20mgml 1 puromycin for 72–120 h. Information on sh/shmirRNAs,
constructs and antibodies are shown in Supplementary Tables S3–S5.
Mouse xenograft experiments. NOD/SCID mice (7–8 weeks, female) were
subcutaneously injected with low-passage 3 105 or 10 105 (dox experiment)
human HCT116 or DLD1 cells lentiviraly transduced with the indicated constructs.
shRNA experiments were performed in blinded manner. For induction, shmirEvi/
Ctrl mice were treated with 1mgml 1 of dox in the drinking water starting from
day 18, when the tumour volumes reach around 125–200mm3. Tumour appear-
ance was monitored once or twice per week by palpating the injection area.
Experiments were terminated when tumours in control group(s) reached 1,200–
1,500mm3. Results for tumour appearance were analysed using R programme and
plotted as Kaplan–Meier plot. P-values were counted with the help of the same
programme by log-rank test. P-values for difference in tumour volumes was cal-
culated by Student’s t-test. Animal welfare and experimental procedures were
performed in accordance with German animal protection law and were approved
by the Regierungspra¨sidium Karlsruhe, Germany (35-9185.81).
Immunohistochemistry. Immunohistochemical studies were performed on par-
afﬁn-embedded slides/sections, and on a Colon-Grade Array with 150 biopsies,
including 30 sections each of normal colon, adenoma, and colon cancer grade 1, 2
and 3 tissues. In addition, serial sections from ﬁve adenocarcinoma and ﬁve normal
colon biopsies were analysed. All samples were analysed as approved by the local
institutional ethics boards. The samples were kindly provided by the NCT tumour
bank for tissue samples.
Expression data analysis. The data from TCGA (http://cancergenome.nih.gov/)
colorectal carcinoma data set (array) was analysed and visualized by Oncomine
(Compendia Bioscience, Ann Arbor, MI, USA; http://www.oncomine.org).
Microarray data are preprocessed by Oncomine in a standardized way by log2
transformation and scaling the median value per microarray to 0. Fold change is
AXIN 1
APC
GSK3-β
Differentiated cells
Transient amplifying
progenitors
Intestinal stem cell
(ISC)
Paneth cell (PA)
Normal colon
Insufficient
activation
Wnt
AXIN 1
APC
GSK3-β
Colon cancer
Sufficient
activation
Tumour cells
APC
15aar SAMP20aarβ-Catenin *
M
ut
at
io
n
Loss of β-catenin degradation ability
Reduced β-catenin binding
Increased Wnt sensitivity
APC
MCR
* β-Catenin degradation
β-Catenin binding
Wnt
Frizzled
Lrp5/6
β-Catenin
Nucleus
Lrp5/6
Frizzled
β-Catenin
Nucleus
Figure 9 | Schematic model on the role of Wnt secretion in APC mutant cells. (a) In normal colon cells, Wnt signalling gradients originating at the
bottom of colonic crypts determine cell identity. Low amounts of Wnt signalling lead to differentiation of epithelial cells of the colon. Under these
conditions, wild-type APC serves as a scaffold, binding b-catenin and catalytic components of the destruction complex, thus sequestering it in the
cytoplasm and causing its degradation. (b) In colon cancer cells, APC is truncated but retains some ability to bind b-catenin and act as a scaffold for the
destruction complex. However, the efﬁciency of b-catenin retention is reduced in a manner related to the length of the truncated APC protein. Thus, APC
truncations sensitize to canonical Wnts, allowing cancer cells to be more sensitive to activation by Wnt ligands, while retaining regulatory activity
throughout the signalling cascade. Further, colon cancer cells acquire the ability to secrete Wnts in an autocrine manner, rendering the tumour increasingly
independent of the original Wnt sources of the colonic crypts.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3610 ARTICLE
NATURE COMMUNICATIONS | 4:2610 | DOI: 10.1038/ncomms3610 | www.nature.com/naturecommunications 11
& 2013 Macmillan Publishers Limited. All rights reserved.
calculated as the difference in the means of the normal colon versus adenocarci-
noma samples.
Cell cycle analysis. Cells were seeded 16 h before analysis (20% of conﬂuence),
collected and stained with 200mgml 1 of propidium iodide, 0.1% sodium azide,
0.1% Triton-X100 and 10 mgml 1 RNAses for 2–4 h. Single cells were analysed for
subG1, S and G2 peaks by ﬂuorescence-activated cell sorting array (BD Bioscience).
Analysis was performed with FlowJo.
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